We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 31st:
Rexahn Pharmaceuticals, Inc. : This clinical stage biopharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 9.5% over the last 60 days.
Rexahn Pharmaceuticals' shares gained 13.9% over the last one month higher than the S&P 500’s increase of 3%. The company possesses a Momentum Score of A.
The E.W. Scripps Company (SSP - Free Report) : This media enterprise has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings rising 15.3% over the last 60 days.
Sesen Bio, Inc. : This late-stage clinical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 18.8% over the last 60 days.
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Image: Bigstock
Top Ranked Momentum Stocks to Buy for August 31st
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 31st:
Rexahn Pharmaceuticals, Inc. : This clinical stage biopharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 9.5% over the last 60 days.
Rexahn Pharmaceuticals, Inc. Price and Consensus
Rexahn Pharmaceuticals, Inc. price-consensus-chart | Rexahn Pharmaceuticals, Inc. Quote
Rexahn Pharmaceuticals' shares gained 13.9% over the last one month higher than the S&P 500’s increase of 3%. The company possesses a Momentum Score of A.
Rexahn Pharmaceuticals, Inc. Price
Rexahn Pharmaceuticals, Inc. price | Rexahn Pharmaceuticals, Inc. Quote
The E.W. Scripps Company (SSP - Free Report) : This media enterprise has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings rising 15.3% over the last 60 days.
E.W. Scripps Company (The) Price and Consensus
E.W. Scripps Company (The) price-consensus-chart | E.W. Scripps Company (The) Quote
E.W. Scripps' shares gained 11.7% over the last one month. The company possesses a Momentum Score of A.
E.W. Scripps Company (The) Price
E.W. Scripps Company (The) price | E.W. Scripps Company (The) Quote
Sesen Bio, Inc. : This late-stage clinical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 18.8% over the last 60 days.
Eleven Biotherapeutics, Inc. Price and Consensus
Eleven Biotherapeutics, Inc. price-consensus-chart | Eleven Biotherapeutics, Inc. Quote
Sesen Bio's shares gained 17.1% over the last one month. The company possesses a Momentum Score of A.
Eleven Biotherapeutics, Inc. Price
Eleven Biotherapeutics, Inc. price | Eleven Biotherapeutics, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>